Ascendis Pharma Statistics
Total Valuation
Ascendis Pharma has a market cap or net worth of $14.42 billion. The enterprise value is $14.72 billion.
Important Dates
The last earnings date was Wednesday, February 11, 2026, after market close.
| Earnings Date | Feb 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Ascendis Pharma has 61.38 million shares outstanding. The number of shares has increased by 4.69% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 61.38M |
| Shares Change (YoY) | +4.69% |
| Shares Change (QoQ) | +0.44% |
| Owned by Insiders (%) | 0.77% |
| Owned by Institutions (%) | 81.84% |
| Float | 60.91M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 42.86 |
| PS Ratio | 17.06 |
| Forward PS | 10.72 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 269.67 |
| P/OCF Ratio | 227.93 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 17.41 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 275.28 |
Financial Position
The company has a current ratio of 1.04
| Current Ratio | 1.04 |
| Quick Ratio | 0.72 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | 19.14 |
| Interest Coverage | -1.69 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -6.86% |
| Return on Invested Capital (ROIC) | -11.67% |
| Return on Capital Employed (ROCE) | -58.44% |
| Weighted Average Cost of Capital (WACC) | 6.66% |
| Revenue Per Employee | $711,121 |
| Profits Per Employee | -$225,181 |
| Employee Count | 1,189 |
| Asset Turnover | 0.58 |
| Inventory Turnover | 0.32 |
Taxes
In the past 12 months, Ascendis Pharma has paid $18.06 million in taxes.
| Income Tax | 18.06M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +54.16% in the last 52 weeks. The beta is 0.43, so Ascendis Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.43 |
| 52-Week Price Change | +54.16% |
| 50-Day Moving Average | 217.63 |
| 200-Day Moving Average | 195.63 |
| Relative Strength Index (RSI) | 61.01 |
| Average Volume (20 Days) | 729,616 |
Short Selling Information
| Short Interest | 2.90M |
| Short Previous Month | 3.16M |
| Short % of Shares Out | 5.69% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 4.43 |
Income Statement
In the last 12 months, Ascendis Pharma had revenue of $845.52 million and -$267.74 million in losses. Loss per share was -$4.42.
| Revenue | 845.52M |
| Gross Profit | 734.08M |
| Operating Income | -160.00M |
| Pretax Income | -249.68M |
| Net Income | -267.74M |
| EBITDA | -154.30M |
| EBIT | -160.00M |
| Loss Per Share | -$4.42 |
Full Income StatementBalance Sheet
The company has $723.31 million in cash and $1.02 billion in debt, with a net cash position of -$300.28 million or -$4.89 per share.
| Cash & Cash Equivalents | 723.31M |
| Total Debt | 1.02B |
| Net Cash | -300.28M |
| Net Cash Per Share | -$4.89 |
| Equity (Book Value) | -191.17M |
| Book Value Per Share | -3.11 |
| Working Capital | 46.49M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $63.28 million and capital expenditures -$9.96 million, giving a free cash flow of $53.49 million.
| Operating Cash Flow | 63.28M |
| Capital Expenditures | -9.96M |
| Free Cash Flow | 53.49M |
| FCF Per Share | $0.87 |
Full Cash Flow StatementMargins
Gross margin is 86.82%, with operating and profit margins of -18.92% and -31.67%.
| Gross Margin | 86.82% |
| Operating Margin | -18.92% |
| Pretax Margin | -29.53% |
| Profit Margin | -31.67% |
| EBITDA Margin | -18.25% |
| EBIT Margin | -18.92% |
| FCF Margin | 6.33% |
Dividends & Yields
Ascendis Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.69% |
| Shareholder Yield | -4.69% |
| Earnings Yield | -1.86% |
| FCF Yield | 0.37% |
Dividend DetailsAnalyst Forecast
The average price target for Ascendis Pharma is $277.13, which is 17.93% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $277.13 |
| Price Target Difference | 17.93% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (5Y) | 35.74% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Ascendis Pharma has an Altman Z-Score of 1.17 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.17 |
| Piotroski F-Score | 4 |
